AzTrials
AzTrials

Survival of Bacteria on Skin After Using Different SoapsNCT02012348

Analysis of the Effect of Antimicrobial Soap on Bacterial Survival

A study testing Antibacterial soap with triclocarban and Antibacterial soap + benzalkonium chloride in people with Survival of Bacteria on Skin After Using Different Soaps, run by University of California, San Diego at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will recruit up to 10 healthy volunteers. An avirulent strain of S. pyogenes will be applied to their forearms after washing each of their forearms with different types of soap, one with an antimicrobial compound, and the other without an antimicrobial compound. Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
What is being tested?
Antibacterial soap with triclocarban and Antibacterial soap + benzalkonium chloride
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
30 participants
Where
1 siteUnited States
Study dates
Dec 2013to Jul 2015
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Those who meet all of the following criteria are eligible for enrollment into the study:
  • Age 18-60 years
  • Male or female of any race and ethnicity
  • Subject agrees to comply with study requirements.

Who cannot join

  • Subjects with severe medical condition(s) that in the view of the investigator prohibits participation in the study
  • Dermatologic disease such as psoriasis or atopic dermatitis which may have inherently abnormal antimicrobial peptide levels
  • Subject has Netherton's syndrome or other genodermatoses that result in a defective epidermal barrier
  • Pregnant or nursing females
  • Immunocompromised subjects (e.g., lymphoma, HIV/AIDS, Wiskott-Aldrich Syndrome), or with a history of active or malignant disease (excluding non-melanoma skin cancer) as determined by the participant's medical history.
  • Subjects with a history of psychiatric disease or history of alcohol or drug abuse that would interfere with the ability to comply with the study protocol
Show all 16Show fewer
  • Subjects with significant concurrent medical condition(s) at screening that in the view of the investigator prohibits participation in the study (e.g., severe concurrent allergic disease, condition associated with malignancy, and condition associated with immunosuppression)
  • Active viral or fungal skin infections at the target areas
  • Are currently receiving lithium, antimalarials, or intramuscular gold now or within the last 4 weeks.
  • Ongoing participation in an investigational drug trial
  • Use of any oral or topical antibiotic during the study and up to one week prior to entering the study
  • Use of any local topical medications less than one week prior to screening
  • Use of any systemic immunosuppressive therapy less than four weeks prior to screening.
  • Subjects with a history of or propensity to developing reactions after use of over the counter cleansers
  • Subjects with diabetes
  • Injured, broken skin that, per the investigator, may cause injury if exposed to low virulence GAS.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UCSD Dermatology

    San Diego, California, 92122

Other trials in United States

About this study

This study will recruit up to 10 healthy volunteers. An avirulent strain of S. pyogenes will be applied to their forearms after washing each of their forearms with different types of soap, one with an antimicrobial compound, and the other without an antimicrobial compound. After several hours of incubation, the subject's forearms will be swabbed for bacteria. The forearms will then be cleansed with antibacterial soap and water followed by 70% ethanol. The bacterial swabs will be analyzed and compared between the different soaps that were used to cleanse each digit prior to the application of S. pyogenes. The investigator expects the number of bacteria surviving on the skin of forearms washed with antimicrobial soaps will be fewer than with control soap.

Read the detailed description

The study timeline will be as follows:

Day -7 to -1 - After obtaining informed consent, potential participants will be screened. A brief history and physical exam will be done on those who meet enrollment criteria. They will be assigned a start date to coincide with Day 0 below.

Day 0 - Participants will be instructed not to shower on this day. They may shower the evening before Day 0, however starting at midnight on Day 0, the participant will be advised not to shower. They will also be asked to wear a shirt with long sleeves. Significant exercise, sunbathing, and the use of creams or lotions on the forearms should also be avoided starting on Day 0, and these restrictions will remain in place until all Day 1 study-related procedures are completed. In the late afternoon on this day, the subject will have six (6) 2 cm x 2 cm squares drawn on each forearm using a skin marker. The volar forearms will be washed with soap, taking care to not remove the skin markings. One forearm will be washed with a soap containing an antibacterial compound. The other forearm will be washed using a control soap that does not contain an antibacterial compound. Each washing will consist of the application of 1.5 mL of test product to the volar forearm. A lather will be generated for 20 seconds using a gloved hand. The forearm will be rinsed with running tap water for 30 seconds and allowed to air-dry. Each forearm will be wrapped in gauze once dry. The gauze should be kept dry and in place until removed by the study staff the following day.

Day 1 - On the morning of Day 1, the gauze will be removed from participants' forearms, and 10 µL PBS containing 104 CFU of avirulent Streptococcus pyogenes (strain NZ131 M49) will be applied to the center of each of the squares previously drawn on participants' forearms. The bacteria will be spread within each square to evenly coat the surface of the skin within the square. The bacteria will then be allowed to air dry. Once dry, skin swabs will be rubbed over two of the squares on each forearm to collect a sample of the bacteria on the forearm at that location. After swabbing, these areas will be immediately disinfected with 70% alcohol. The forearms will then be wrapped again in gauze. One hour later, the gauze will be removed, and two more squares on each forearm will be swabbed for bacteria. These squares will then be disinfected with 70% alcohol, and gauze reapplied to the forearms. One hour later (two hours post-washing), the gauze will be removed, and the remaining two squares on each forearm will be swabbed for bacteria. Both forearms will then be washed with 70% ethanol and rinsed with water to remove any remaining bacteria. This will conclude the study-related procedures for Day 1. Participants are then free to shower, sunbathe, exercise and apply any creams or lotions to their forearms until the following week.

These same study procedures as above will be repeated again on Days 7 and 8, however the antibacterial soap will be used to wash one of the forearms will be replaced by a different antibacterial soap. The exact details are described in the paragraphs below.

Day 7 - Participants will be instructed not to shower on this day. They may shower the evening before Day 7, however starting at midnight on Day 7, the participant will be advised not to shower. They will also be asked to wear a shirt with long sleeves. Significant exercise, sunbathing, and the use of creams or lotions on the forearms should also be avoided starting on Day 7, and these restrictions will continue until all Day 8 study-related procedures are completed. In the late afternoon on this day, the subject will have six (6) 2 cm x 2 cm squares drawn on each forearm using a skin marker. The volar forearms will be washed with soap, taking care to not remove the skin markings. One forearm will be washed with a soap containing an antibacterial compound. The other forearm will be washed using a control soap that does not contain an antibacterial compound. Each washing will consist of the application of 1.5 mL of test product to the volar forearm. A lather will be generated for 20 seconds using a gloved hand. The forearm will be rinsed with running tap water for 30 seconds and allowed to air-dry. Each forearm will be wrapped in gauze once dry. The gauze should be kept dry and in place until removed by the study staff the following day.

Day 8 - On the morning of Day 8, the gauze will be removed from participants' forearms, and 10 µL PBS containing 104 CFU of avirulent Streptococcus pyogenes (strain NZ131 M49) will be applied to the center of each of the squares previously drawn on participants' forearms. The bacteria will be spread within each square to evenly coat the surface of the skin within the square. The bacteria will then be allowed to air dry. Once dry, skin swabs will be rubbed over two of the squares on each forearm to collect a sample of the bacteria on the forearm at that location. After swabbing, these areas will be immediately disinfected with 70% alcohol. The forearms will then be wrapped again in gauze. One hour later, the gauze will be removed, and two more squares on each forearm will be swabbed for bacteria. These squares will then be disinfected with 70 alcohol, and gauze reapplied to the forearms. One hour later (two hours post-washing), the gauze will be removed, and the remaining two squares on each forearm will be swabbed for bacteria. Both forearms will then be washed with 70% ethanol and rinsed with water to remove any remaining bacteria. This will conclude all study-related procedures. Participants are then free to shower, sunbathe, exercise and apply any creams or lotions to their forearms.

Being tested
Antibacterial soap with triclocarban, Antibacterial soap + benzalkonium chloride, Control soap
Keywords
bacteria survival, surfactants

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Antibacterial soap with triclocarbanOther

  • Antibacterial soap + benzalkonium chlorideOther

  • Control soapOther

Study groups in NCT02012348
Study groupRoleWhat they receive
Control soapPlacebo comparatorForearms of subjects in this arm will be washed with control (non-antibacterial) soap
Receives: Other: Control soap
Antibacterial soap with triclocarbanExperimentalThe forearms of subjects in this group will be washed with antibacterial soap containing triclocarban
Receives: Other: Antibacterial soap with triclocarban
Antibacterial soap + benzalkonium chlorideActive comparatorThe forearms of subjects in this group will be washed with antibacterial soap containing benzalkonium chloride
Receives: Other: Antibacterial soap + benzalkonium chloride

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Relative GAS Survival

    A skin swab will be used to measure the bacterial survival 30 minutes after bacteria application and soap treatment. The bacteria being applied and subsequently measured is Group A Streptococcus (GAS). The bacterial survival is expressed as abundance of GAS relative to abundance of other bacterial species isolated from the swab.

    Measured: 30 minutes post-bacteria application

Secondary outcomes (1)
  1. Relative GAS Survival

    A skin swab will be used to measure the bacterial survival 1 hour after bacteria application (2 hours post washing with soap). The bacteria being applied and subsequently measured is Group A Streptococcus (GAS). The bacterial survival is expressed as abundance of GAS relative to abundance of other bacterial species isolated from the swab.

    Measured: 1 hour after bacteria application / 2 hours post washing

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Dec 2013 (estimated)
  2. Study startDec 2013
  3. Primary completionJul 2015
  4. Study completionJul 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02012348
Sponsor's protocol ID
UCSD 121622
Status last verified
Sep 2019
First submitted
10 Dec 2013
Last updated
3 Oct 2019
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Antibacterial soap with triclocarban and Antibacterial soap + benzalkonium chloride in people with Survival of Bacteria on Skin After Using Different Soaps, run by University of California, San Diego at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 3 Oct 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Relative GAS Survival (time frame: 30 minutes post-bacteria application). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in